vTv Therapeutics Q2 2023 net loss $5.6M ($0.07/shr); R&D spend up on cadisegliatin; Nasdaq extension granted

vTv Therapeutics Inc.

Net loss of $5.6M ($0.07 per share) vs $3.2M ($0.04) in Q2 2022; no quarterly revenue.
R&D expenses $4.7M, up 113% from $2.2M, driven by cadisegliatin drug product costs.
Cash $12.6M at June 30, 2023, up modestly from $12.1M at Dec 31, 2022.
Nasdaq extended deadline to regain $1 bid compliance to Dec 18, 2023 (granted July 17).
Phase 3 study for cadisegliatin (TTP399) expected to initiate by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

vTv Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 11, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.